medroxyprogesterone acetate


Summary: A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.

Top Publications

  1. Molyneux E, Merrick B, Khanim F, Banda K, Dunn J, Iqbal G, et al. Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497). Br J Haematol. 2014;164:888-90 pubmed publisher
  2. Noguchi L, Richardson B, Baeten J, Hillier S, Balkus J, Chirenje Z, et al. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV. 2015;2:e279-87 pubmed
    ..observational studies have reported that HIV-1 acquisition seems to be higher in women who use depot medroxyprogesterone acetate (DMPA) than in those who do not use hormonal contraception...
  3. Byrne C, Ursin G, Martin C, Peck J, Cole E, Zeng D, et al. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. J Natl Cancer Inst. 2017;109: pubmed publisher
    ..625?mg plus medroxyprogesterone acetate 2.5?mg or placebo...
  4. Balkus J, Palanee Phillips T, Reddy K, Siva S, Harkoo I, Nakabiito C, et al. Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception. J Acquir Immune Defic Syndr. 2017;76:e47-e51 pubmed publisher
    ..Pregnancy incidence in the dapivirine arm versus placebo among women using injectable depot medroxyprogesterone acetate was 0.43% vs. 0.54%, among women using injectable norethisterone enanthate was 1.15% vs...
  5. Krashin J, Stuart G, Garrett J, Spector H, Bryant A, Charm S, et al. Contraception Insurance Coverage and Receipt of Long-Acting Reversible Contraception or Depot Medroxyprogesterone Acetate on the Day of Abortion. Obstet Gynecol. 2017;130:109-117 pubmed publisher
    ..who present for an abortion is associated with obtaining long-acting reversible contraception or depot medroxyprogesterone acetate (DMPA) on the day the abortion is completed...
  6. Pacifici R, Rifas L, McCracken R, Vered I, McMurtry C, Avioli L, et al. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Natl Acad Sci U S A. 1989;86:2398-402 pubmed
    ..Persistent elevation of IL-1 secretion appears to be a feature of postmenopausal osteoporosis. ..
  7. Zhao S, Chlebowski R, Anderson G, Kuller L, Manson J, Gass M, et al. Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res. 2014;16:R30 pubmed publisher
    ..breast cancer risk reduction with conjugated equine estrogens (CEE) and a risk elevation with CEE plus medroxyprogesterone acetate (CEE?+?MPA) were observed in the Women's Health Initiative (WHI) randomized controlled trials...
  8. Westhoff C, Winikoff B. DMPA and HIV: do we need a trial?. Contraception. 2014;90:353 pubmed publisher
  9. Park J, Seong S, Kim T, Kim J, Bae D, Nam J. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer. Gynecol Oncol. 2017;146:39-43 pubmed publisher
    ..However, pre and posttreatment BMIs of ?25kg/m2 were significant predictors for poor treatment response and high recurrence. Therefore, it is important to maintain patients' normal BMIs during progestin therapy. ..

More Information


  1. Yunokawa M, Yoshida H, Watanabe R, Noguchi E, Shimomura A, Shimoi T, et al. Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer. Cancer Chemother Pharmacol. 2017;80:127-134 pubmed publisher
    Predictors of response or disease control with oral medroxyprogesterone acetate (MPA) therapy in patients with metastatic or recurrence endometrial cancer remain to be elucidated...
  2. Jiang S, Kuang Y. Clomiphene citrate is associated with favorable cycle characteristics but impaired outcomes of obese women with polycystic ovarian syndrome undergoing ovarian stimulation for in vitro fertilization. Medicine (Baltimore). 2017;96:e7540 pubmed publisher
    ..Both of the 2 groups used medroxyprogesterone acetate (MPA) for preventing premature luteinizing hormone (LH) surges...
  3. Shifren J, Tseng J, Zaloudek C, Ryan I, Meng Y, Ferrara N, et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab. 1996;81:3112-8 pubmed
    ..with these in vivo results, the treatment of isolated human endometrial cells with estradiol (E2), medroxyprogesterone acetate (MPA), or E2 plus MPA significantly increased VEGF mRNA expression over the control value by 3.1-, 2...
  4. Martin H, Nyange P, Richardson B, Lavreys L, Mandaliya K, Jackson D, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1998;178:1053-9 pubmed
    ..Women who used depo medroxyprogesterone acetate (DMPA) had an increased incidence of HIV-1 infection (hazard ratio [HR], 2...
  5. Díaz Flaqué M, Galigniana N, Beguelin W, Vicario R, Proietti C, Russo R, et al. Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Res. 2013;15:R118 pubmed publisher
    ..We here provided novel insight into the paradox of PR action as well as new tools to identify the subgroup of ER+/PR + patients unlikely to respond to ER-targeted therapies. ..
  6. Spieler J. Sayana® Press: can it be a "game changer" for reducing unmet need for family planning?. Contraception. 2014;89:335-8 pubmed publisher
  7. Shenoy C, Khan Z, Zheng Y, Jones T, Khazaie K, Daftary G. Progressive Fibrosis: A Progesterone- and KLF11-Mediated Sexually Dimorphic Female Response. Endocrinology. 2017;158:3605-3619 pubmed publisher
    ..Ovariectomized animals were selectively supplemented with estradiol, medroxyprogesterone acetate (MPA), or dihydrotestosterone; fibrosis was only observed in mice exposed to MPA...